Virtu KCG Holdings’s Cytokinetics CYTK Stock Holding History

Virtu KCG Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$172K	Sell	14,238 -8,081	-36%	-$112K	﹤0.01%	2229
2017 Q1	$287K	Buy	+22,319	New	+$261K	0.01%	1997
2016 Q2	–	Sell	-10,382	Closed	-$73K	–	3001
2016 Q1	$73K	Sell	10,382 -28,864	-74%	-$211K	﹤0.01%	2387
2015 Q4	$411K	Buy	+39,246	New	+$385K	0.01%	1772
2015 Q2	–	Sell	-17,198	Closed	-$117K	–	3371
2015 Q1	$117K	Sell	17,198 -3,054	-15%	-$22.8K	﹤0.01%	2609
2014 Q4	$162K	Buy	+20,252	New	+$86.9K	﹤0.01%	3008
2014 Q1	–	Sell	-19,430	Closed	-$126K	–	3598
2013 Q4	$126K	Sell	19,430 -6,874	-26%	-$45.2K	﹤0.01%	3362
2013 Q3	$199K	Buy	+26,304	New	+$282K	﹤0.01%	3134

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Virtu KCG Holdings's CYTK Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Cytokinetics (CYTK) stake by 36% in Q2 2017, selling an estimated $112K and leaving 14,238 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #2229.

Virtu KCG Holdings first reported a position in CYTK in Q3 2013 and has held it in 8 quarters since. The position peaked at $411K in Q4 2015. 136 funds tracked by Wall St. Rank hold CYTK as of Q2 2017.

Virtu KCG Holdings held 14,238 shares of Cytokinetics worth $172K as of Q2 2017.
Virtu KCG Holdings sold 8,081 Cytokinetics shares in Q2 2017, an estimated $112K.
Cytokinetics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2229 holding.
Virtu KCG Holdings first reported a position in Cytokinetics in Q3 2013 and has held it in 8 quarters since.
Virtu KCG Holdings's Cytokinetics position peaked at $411K in Q4 2015.
136 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.